255 related articles for article (PubMed ID: 31243239)
1. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
[TBL] [Abstract][Full Text] [Related]
2. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer.
Okawa S; Kayatani H; Fujiwara K; Ozeki T; Takada K; Iwamoto Y; Minami D; Sato K; Shibayama T
Intern Med; 2019; 58(5):699-702. PubMed ID: 30828042
[TBL] [Abstract][Full Text] [Related]
5. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
6. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
7. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
8. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
9. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
10. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
12. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
[TBL] [Abstract][Full Text] [Related]
13. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
14. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
15. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
[TBL] [Abstract][Full Text] [Related]
16. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
18. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
20. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
